As the number of confirmed COVID-19 cases worldwide approaches 4 million and the pandemic could be with us for months or years, we look at who can access drugs like remdesivir, being developed by pharmaceutical giant Gilead, which has the patent for the drug and is poised to make massive profits. We look at how much drugs like remdesivir will cost, and who can access them, with writer Achal Prabhala, coordinator of the AccessIBSA project, which campaigns for access to medicines in India, Brazil and South Africa.
Please check back later for full transcript.
Yes, we really mean it – your gift makes a difference.
Did you know that of the millions of people who read Truthout, fewer than 1 percent make a donation? But even with that small number who give, Truthout is still overwhelmingly donor-funded. Every donation that comes our way makes an outsized impact for every single one of our readers.
If you can find a few dollars here or there to support the independent, always-honest journalism we produce, please consider making a donation. All gifts are tax-deductible and go directly to funding our justice-driven work. Will you give today?